H.C. Wainwright Reiterates Buy Rating on Regeneron Pharma (REGN) After Another Dupixent Win
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Price: $805.93 +0.30%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
H.C. Wainwright analyst Michael G. King, Jr. notes Regeneron Pharma (NASDAQ: REGN) Dupixent scored another with Atopic Dermatitis.
As a result, the firm reiterated a Buy rating and $787.00 price target on REGN.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $663.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
- York Space Systems (YSS) PT Lowered to $15 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
